Towns wants answers on J&J's alleged "phantom recall"
This article was originally published in The Tan Sheet
Rep. Edolphus Towns investigates whether Johnson & Johnson and subsidiary McNeil Consumer Healthcare hired contractors to buy all of a small Motrin stock-keeping unit as part of a "phantom recall" in 2008. "The company's motivation was apparently to save itself the embarrassment and potential financial loss associated with a recall," said Towns, chairman of the House Oversight and Government Reform Committee. The New York Democrat June 3 sent a 1letter to contractor WIS and a separate 2letter to Inmar Inc. - whose subsidiary Carolina Supply Chain Services may have recruited WIS to purchase the affected Motrin, Towns said. The letters ask the firms for details on what J&J contracted them to do. J&J OTC executive Colleen Goggins testified May 27 she was unaware of the contractors secretly purchasing the product, which failed to meet dissolution standards and was recalled formally in 2009 (3"The Tan Sheet" May 31, 2010)
You may also be interested in...
Congress Wants More Answers From J&J On "Phantom Recall"
Johnson & Johnson's response to a congressional inquiry regarding the alleged "phantom recall" of a Motrin product left a House committee chairman considering whether to subpoena additional information
J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues
FDA's drug center referred its review of Johnson & Johnson's manufacturing operations to the Office of Criminal Investigations, which will determine whether there is criminal liability in the quality control lapses that led to extensive recalls of OTC drugs
Long-Term Data Boost Novartis And Roche SMA Challenge To Biogen’s Spinraza
New long-term data from Novartis’s Zolgensma and Roche’s Erysdi will help close the gap on Biogen’s market leader Spinraza, but the three therapies look set to develop distinct or even complementary roles as the market matures.